Application of botulinum toxin in pain management

Korean Journal of Pain

Volumn 24, Issue 1, 2011, Pages 1-6

  Sim, Woo Seog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Botulinum toxin; Pain

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN; NORADRENALIN; SUBSTANCE P;

ANALGESIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTHRITIS; BACKACHE; BLEPHAROSPASM; BRUXISM; CERVICAL DYSTONIA; CHRONIC DAILY HEADACHE; CHRONIC PAIN; CHRONIC PROSTATITIS; COMPLEX REGIONAL PAIN SYNDROME; DETRUSOR DYSSYNERGIA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DYSTONIA; ENZYME REPRESSION; FATIGUE; FEVER; HEADACHE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; IMMUNOGENICITY; INJECTION PAIN; INTERSTITIAL CYSTITIS; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; KNEE PAIN; LETHARGY; MIGRAINE; MUSCLE ATROPHY; MUSCLE HYPOTONIA; MUSCLE SPASM; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; MYOFASCIAL PAIN; NECK PAIN; NEURALGIA; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; OROMANDIBULAR DYSTONIA; PELVIS PAIN SYNDROME; PLANTAR FASCIITIS; PRIMARY HEADACHE; PROTEIN SECRETION; PTOSIS; REVIEW; SEGMENTAL DYSTONIA; SEROTYPE; SKELETAL MUSCLE; SKIN BRUISING; SPASMODIC DYSPHONIA; SPASTICITY; STRABISMUS; STUTTERING; TEMPOROMANDIBULAR JOINT DISORDER; TENSION HEADACHE; TRIGEMINUS NEURALGIA; VAGINISM; VISUAL IMPAIRMENT; VULVODYNIA; XEROSTOMIA;

EID: 84856870002     PISSN: 20059159     EISSN: 20930569     Source Type: Journal    
DOI: 10.3344/kjp.2011.24.1.1     Document Type: Review

References (26)

1. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002; 18(Suppl 6): S142-6.
2. Colhado OC, Boeing M, Ortega LB. Botulinum toxin in pain treatment. Rev Bras Anestesiol 2009; 59: 366-81.
3. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002; 18(Suppl 6): S119-24.
4. Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain 2003; 4: 159-65.
5. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005; 20: 1152-60.
6. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-9.
7. Apostol C, Abdi S, Moeller-Bertram T, Smith HS, Argoff CE, Wallace M. Botulinum toxins for the treatment of pain. In: Current therapy in pain. Edited by Smith HS. Philadelphia, Saunders. 2009, pp 489-98.
8. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 2002; 18(Suppl 6): S125-32.
9. Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 2006; 102: 509-16.
10. Göbel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001; 91: 195-9.
11. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, Botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005; 25: 604-11.
12. Fishman LM, Konnoth C, Rozner B. Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study. Am J Phys Med Rehabil 2004; 83: 42-50.
13. Lang AM. Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil 2004; 83: 198-202.
14. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R; Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006; 125: 82-8.
15. von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 2003; 61: 774-8.
16. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil 2005; 84: 649-54.
17. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001; 56: 1290-3.
18. Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain 2002; 18(Suppl 6): S155-62.
19. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40: 445-50.
20. Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26: 790-800.
21. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebocontrolled study. Cephalalgia 2004; 24: 838-43.
22. Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 2004; 44: 801-5.
23. Freund BJ, Schwartz M. Use of botulinum toxin in chronic whiplash-associated disorder. Clin J Pain 2002; 18(Suppl 6): S163-8.
24. Mahowald ML, Krug HE, Singh JA, Dykstra D. Botulinum toxin for osteoarticular pain. In: Botulinum toxin. Therapeutic clinical practice and science. Edited by Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH. Philadelphia, Saunders. 2009, pp 295-306.
25. Smith PP, Smith CP. Botulinum toxin in the treatment of chronic pelvic pain syndromes In: Botulinum toxin. Therapeutic clinical practice and science. Edited by Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH. Philadelphia, Saunders. 2009, pp 257-68.
26. Hallett M. Potential new therapeutic indications for botulinum neurotoxins. In: Botulinum toxin. Therapeutic clinical practice and science. Edited by Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH. Philadelphia, Saunders. 2009, pp 367-72.RAJA2